Enhanced sensitivity to benzodiazepines in active cocaine-abusing subjects: a PET study.
OBJECTIVE
Because cocaine enhances dopamine brain activity and dopamine signals are transferred through gamma-aminobutyric acid pathways, the authors hypothesized GABA-ergic disruption in cocaine-abusing subjects. This study tests this hypothesis.


METHODS
GABA brain function was assessed indirectly by measuring the brain metabolic responses to lorazepam, a drug that facilitates GABA neurotransmission. Thirteen current cocaine-abusing subjects and 14 comparison subjects were scanned twice with positron emission tomography and [18F]fluorodeoxyglucose; the first scan was obtained after placebo administration and the second after lorazepam administration (30 micrograms/kg).


RESULTS
Despite significantly higher plasma lorazepam concentrations in comparison subjects than in cocaine-abusing subjects, lorazepam-induced decrements in whole brain metabolism were significantly greater in cocaine-abusing (mean = 21%, SD = 13%) than in comparison (mean = 13%, SD = 7%) subjects. These differences were largest in striatum, thalamus, and parietal cortex. Lorazepam-induced sleepiness in cocaine-abusing subjects was intense and was significantly greater than in comparison subjects, and it was correlated with lorazepam-induced changes in thalamic metabolism. Whereas regional metabolic measures during placebo administration were significantly higher in cocaine-abusing subjects than in comparison subjects, the measures during lorazepam administration were equivalent for both groups.


CONCLUSIONS
The enhanced sensitivity to lorazepam in cocaine-abusing subjects suggests disruption of GABA pathways that may reflect, in part, cocaine withdrawal. The intense sleepiness induced by lorazepam in some of the abusers, despite their significantly lower plasma concentrations, should alert clinicians of the potential toxicity from accentuated responses to sedative hypnotics in active cocaine-abusing subjects.
Volkow
N D
ND
Medical Department, Brookhaven National Laboratory, NY 11973, USA. volkow@bnl.gov
Wang
G J
GJ
Fowler
J S
JS
Hitzemann
R
R
Gatley
S J
SJ
Dewey
S S
SS
Pappas
N
N
D000328:Adult; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000378:metabolism*; D019970:Cocaine-Related Disorders / Q000097:blood / Q000000981:diagnostic imaging* / Q000378:metabolism*; D005260:Female; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D008140:Lorazepam / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology*; D008297:Male; D018079:Receptors, GABA / Q000187:drug effects*; D012890:Sleep / Q000187:drug effects; D013375:Substance Withdrawal Syndrome / Q000209:etiology; D014055:Tomography, Emission-Computed
D018079:Receptors, GABA; D019788:Fluorodeoxyglucose F18; D005947:Glucose; D008140:Lorazepam